Search - tctmd.com

Displaying 341 - 360 of 420

Sort: Relevancy | Date

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

COMBO Stent Achieves Neointimal Regression at 24 Months

September 15, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

CTO-IVUS Trial Supports IVUS Guidance for CTO PCI

September 14, 2014

Presentation TCT 2014

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, J. Dawn Abbott

September 13, 2014

News Conference News TCT 2014

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

September 13, 2014

News Conference News TCT 2014

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

September 13, 2014

News Conference News TCT 2014

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

September 13, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Presenter: George Dangas

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

News Conference News TCT 2013

SORT-OUT VI: Permanent Polymer ZES Noninferior to Biodegradable BES in All-Comers Study

October 30, 2013

News Conference News TCT 2013

Memories of TCT 1988 and Beyond: Julio C. Palmaz, MD

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

Advertisement

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

Keynote Address Focuses on Newer DES, Problematic Subgroups

COMBO Stent Achieves Neointimal Regression at 24 Months

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

CTO-IVUS Trial Supports IVUS Guidance for CTO PCI

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

SORT-OUT VI: Permanent Polymer ZES Noninferior to Biodegradable BES in All-Comers Study

Memories of TCT 1988 and Beyond: Julio C. Palmaz, MD

Innovation in Intervention: Perspectives from Industry

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content